Platinum-sensitive recurrent ovarian cancer: chemotherapy-bevacizumab combo tops standard

  • Pfisterer J & al.
  • Lancet Oncol
  • 16 Apr 2020

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with platinum-sensitive recurrent ovarian cancer, carboplatin+pegylated liposomal doxorubicin+bevacizumab significantly prolonged survival vs standard carboplatin+gemcitabine+bevacizumab in this phase 3 trial.

Why this matters

  • These findings support carboplatin+pegylated liposomal doxorubicin+bevacizumab as a new standard regimen for patients with disease amenable to platinum-based and antiangiogenic treatment.

Study design

  • Phase 3, multicenter AGO-OVAR 2.21 study.
  • 682 patients with platinum-sensitive recurrent epithelial ovarian cancer were randomly assigned to receive carboplatin+bevacizumab with either gemcitabine (standard group) or pegylated liposomal doxorubicin (doxorubicin group).
  • Funding: F. Hoffmann-La Roche.

Key results

  • The median follow-up for PFS at data cutoff was 12.4 months in the doxorubicin group and 11.3 months in the standard group.
  • Median PFS was significantly longer in the doxorubicin group:
    • 13.3 vs 11.6 months.
    • HR, 0.81 (P=.012).
  • Median OS was significantly improved in the doxorubicin group:
    • 31.9 vs 27.8 months.
    • HR, 0.81 (stratified log-rank P=.032).
  • The most common grade 3/4 adverse events were hypertension and neutropenia.
  • Serious adverse event rate was 10% in the doxorubicin group and 9% in the standard group.
  • 1 treatment-related death was reported in the doxorubicin group.

Limitations

  • Open-label design.